What is Hepion Pharmaceuticals Operating Cash Flow per Share?
Hepion Pharmaceuticals's operating cash flow per share for the
three
months ended in Dec. 2023 was $-2.04.
Hepion Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.38.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 32.40% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 61.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Hepion Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:
HEPA'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -41.2 Med: 50.2 Max: 82.8
Current: 32.4
During the past 11 years, Hepion Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 82.80% per year. The lowest was -41.20% per year. And the median was 50.20% per year.
HEPA's 3-Year OCF Growth Rate is ranked better than 80.66% of 1241
companies
in the Biotechnology industry
Industry Median: 3.7
vs HEPA: 32.40
Hepion Pharmaceuticals Operating Cash Flow per Share Historical Data
The historical data trend for Hepion Pharmaceuticals's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Hepion Pharmaceuticals Operating Cash Flow per Share Chart
Competitive Comparison of Hepion Pharmaceuticals's Operating Cash Flow per Share
For the Biotechnology subindustry, Hepion Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hepion Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hepion Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Hepion Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.
Hepion Pharmaceuticals Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Hepion Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hepion Pharmaceuticals Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Hepion Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Hepion Pharmaceuticals (Hepion Pharmaceuticals) Business Description
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HEPA has been successfully added to your 